跳至主要内容
临床试验/NCT04438330
NCT04438330已完成不适用

The Immunological Profile of Nickel Dermatitis

National Allergy Research Center, Denmark2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2021年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
26
试验地点
2
主要终点
mRNA Nanostring screening

研究概览

简要总结

A dose-response study on the immune phenotype of allergic nickel dermatitis on a previously exposed skin area.

详细描述

Clinically controlled study comprising 15 people with known nickel allergy and 15 healthy persons as control group. At the Department of Allergy and Dermatology, Gentofte Hospital, test participants will be exposed to nickel sulfate in a patch test on their back, which will create an eczema reaction in people with nickel allergy and induce skin resident T-cells. The resident T-cells will enhance further exposure. The eczema is healed over 3-4 weeks, after which the same areas are again exposed to nickel sulfate at different concentrations in a patch test. Skin biopsies of the exposed areas are taken and the immune phenotype is analyzed trough Nanostring RNA technologies of around 600 immunerelated genes.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be able to understand the written and oral participant information in Danish.
  • Previously proven nick allergy by patch testing within the last 5 years, for the nickel allergic test participants.

排除标准

  • Pregnancy and / or breastfeeding.
  • Systemic immunomodulatory treatments within the last 14 days.
  • Local treatments of selected skin areas, such as applying hormone cream within the last two weeks or applying cream / lotion within 24 hours up to sample collection.
  • Allergy to local anesthesia.
  • Exposed to solar or sunlight on the back within 21 days.
  • History of inflammatory skin diseases, asthma, Diabetes Mellitus, hives or arthritis (exclusion criteria only for participation in the healthy control group).
  • Participation in another scientific experiment within the last 4 weeks. risks,

结局指标

主要结局

mRNA Nanostring screening

时间窗: 1 month

Screening of 600 immune-related genes

次要结局

  • Protein verification(2 month)

研究者

发起方
National Allergy Research Center, Denmark
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验